phenylurea compounds

Summary

Top Publications

  1. ncbi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
  2. ncbi Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Ann Lii Cheng
    National Taiwan University Hospital, Taipei, Taiwan
    Lancet Oncol 10:25-34. 2009
  3. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
  4. ncbi Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    Brian I Rini
    Cleveland Clinic Taussig Cancer Institute, Main Campus, Euclid Avenue, Cleveland, OH 44195, USA
    Lancet 378:1931-9. 2011
  5. ncbi Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3312-8. 2009
  6. ncbi Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    Scott M Wilhelm
    Bayer HealthCare Pharmaceuticals, 340 Changebridge Road, P O Box 1000, Montville, NJ 07045 1000, USA
    Mol Cancer Ther 7:3129-40. 2008
  7. ncbi Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    Li Liu
    Department of Cancer Biology, Bayer HealthCare Pharmaceuticals, West Haven, Connecticut 06516, USA
    Cancer Res 66:11851-8. 2006
  8. ncbi Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
  9. ncbi Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
    Scott M Wilhelm
    Bayer HealthCare Pharmaceuticals, Montville, NJ, USA
    Int J Cancer 129:245-55. 2011
  10. ncbi Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
    Daniel Y C Heng
    FRCPC, Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
    J Clin Oncol 27:5794-9. 2009

Detail Information

Publications277 found, 100 shown here

  1. ncbi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  2. ncbi Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Ann Lii Cheng
    National Taiwan University Hospital, Taipei, Taiwan
    Lancet Oncol 10:25-34. 2009
    ....
  3. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
    ..These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis...
  4. ncbi Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    Brian I Rini
    Cleveland Clinic Taussig Cancer Institute, Main Campus, Euclid Avenue, Cleveland, OH 44195, USA
    Lancet 378:1931-9. 2011
    ....
  5. ncbi Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3312-8. 2009
    ....
  6. ncbi Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    Scott M Wilhelm
    Bayer HealthCare Pharmaceuticals, 340 Changebridge Road, P O Box 1000, Montville, NJ 07045 1000, USA
    Mol Cancer Ther 7:3129-40. 2008
    ..In particular, preclinical evidence that supports the different mechanisms of action of sorafenib is discussed...
  7. ncbi Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    Li Liu
    Department of Cancer Biology, Bayer HealthCare Pharmaceuticals, West Haven, Connecticut 06516, USA
    Cancer Res 66:11851-8. 2006
    ....
  8. ncbi Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
    ..We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma...
  9. ncbi Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
    Scott M Wilhelm
    Bayer HealthCare Pharmaceuticals, Montville, NJ, USA
    Int J Cancer 129:245-55. 2011
    ..These data demonstrate that regorafenib is a well-tolerated, orally active multikinase inhibitor with a distinct target profile that may have therapeutic benefit in human malignancies...
  10. ncbi Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
    Daniel Y C Heng
    FRCPC, Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
    J Clin Oncol 27:5794-9. 2009
    ..There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF) -targeted therapy...
  11. ncbi Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
    Wei Tien Tai
    National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan
    J Hepatol 55:1041-8. 2011
    ..Here, we report that sorafenib inhibits HCC via a kinase-independent mechanism: SHP-1 dependent STAT3 inactivation...
  12. ncbi Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
    Scott Wilhelm
    Department of Cancer Research, Bayer Pharmaceuticals Corp, West Haven, Connecticut 06516, USA
    Nat Rev Drug Discov 5:835-44. 2006
    ....
  13. pmc Phase II trial of sorafenib in advanced thyroid cancer
    Vandana Gupta-Abramson
    Developmental TherapeuticsProgram of the Abramson CancerCenter, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Oncol 26:4714-9. 2008
    ....
  14. pmc Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
    T Eisen
    Royal Marsden Hospital, Downs Road, Surrey SMT 5PT, UK
    Br J Cancer 95:581-6. 2006
    ..i.d.). Ongoing trials in advanced melanoma are evaluating sorafenib combination therapies...
  15. pmc Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Robert G Maki
    Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
    J Clin Oncol 27:3133-40. 2009
    ..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
  16. ncbi Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 27:4462-8. 2009
    ....
  17. pmc Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
    Catherine C Smith
    Division of Hematology Oncology, University of California, San Francisco, California 94143, USA
    Nature 485:260-3. 2012
    ..Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML. AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts...
  18. ncbi Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
    Yong S Chang
    Department of Protein Therapeutics, Bayer Research Center, Bayer HealthCare, Pharmaceuticals, 400 Morgan Lane, West Haven, CT 06516, USA
    Cancer Chemother Pharmacol 59:561-74. 2007
    ..The effect of sorafenib on tumor growth and tumor histology was assessed in both ectopic and orthotopic mouse models of RCC...
  19. ncbi Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
    Marie José Blivet-Van Eggelpoël
    UPMC Univ Paris 06, UMR_S 938, F 75012 Paris, France
    J Hepatol 57:108-15. 2012
    ..However, primary and acquired resistance is observed in patients. We examined whether gefitinib, which inhibits both epidermal growth factor receptor (EGFR) and HER-3 phosphorylation, could improve HCC cell response to sorafenib...
  20. ncbi Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1
    S Huber
    Third Department of Medicine, Technical University, Munich, Germany
    Leukemia 25:838-47. 2011
    ..Conclusively, sorafenib is highly active in CLL and may compose a new therapeutic option for patients who relapse after immunochemotherapy...
  21. pmc A phase II trial of sorafenib in metastatic melanoma with tissue correlates
    Patrick A Ott
    Department of Medical Oncology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e15588. 2010
    ..Sorafenib monotherapy in patients with metastatic melanoma was explored in this multi-institutional phase II study. In correlative studies the impact of sorafenib on cyclin D1 and Ki67 was assessed...
  22. ncbi Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
    Kuen Feng Chen
    Department of Medical Research, National Taiwan University Hospital, No 7, Chung Shan S Rd, Taipei, Taiwan
    J Pharmacol Exp Ther 337:155-61. 2011
    ..In conclusion, activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in HCC, and the combination of sorafenib and MK-2206, an Akt inhibitor, overcomes the resistance at clinical achievable concentrations...
  23. pmc PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways
    Roberto Gedaly
    Department of Surgery, University of Kentucky, College of Medicine, Lexington, KY 40536, USA
    Anticancer Res 30:4951-8. 2010
    ..This study reports how sorafenib (a multi-kinase inhibitor) and PI-103 (a dual PI3K/mTOR inhibitor) alone and in combination inhibit the proliferation of the HCC cell line, Huh7...
  24. ncbi Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
    Giorgio Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Regione Gonzole 10, Orbassano, Torino, Italy 10043
    J Clin Oncol 28:1835-42. 2010
    ..4%), hand-foot skin reaction (7.8%), and diarrhea (3.5%). CONCLUSION No clinical benefit was observed from adding sorafenib to CP chemotherapy as first-line treatment for NSCLC...
  25. ncbi Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, CIBERehd, Institut d Investigacions Biomédiques, August Pi i Sunyer, Hospital Clinic Barcelona, Barcelona, Spain
    Clin Cancer Res 18:2290-300. 2012
    ..One of the objectives of the phase III, randomized, controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial was to explore the ability of plasma biomarkers to predict prognosis and therapeutic efficacy...
  26. ncbi EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
    Zakaria Ezzoukhry
    Inserm U1088, Faculte de Medecine, Universite de Picardie Jules Verne, Amiens, France
    Int J Cancer 131:2961-9. 2012
    ..Our findings bear possible implications for the improvement of the efficacy of sorafenib in HCC, and might be useful for the identification of predictive biomarkers in this context...
  27. ncbi Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3
    Wei Tien Tai
    Department of Medical Research, National Taiwan University Hospital, Chung Shan S Rd, Taipei 100, Taiwan
    Mol Cancer Ther 11:452-63. 2012
    ..In conclusion, dovitinib induces significant apoptosis in HCC cells and sorafenib-resistant cells via SHP-1-mediated inhibition of STAT3...
  28. ncbi Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro
    Anders Ullen
    Department of Oncology Pathology, Cancer Centrum Karolinska, Karolinska Institutet, 17176 Stockholm, Sweden
    Int J Oncol 37:15-20. 2010
    ....
  29. ncbi Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis
    Ying Hong Shi
    Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
    Autophagy 7:1159-72. 2011
    ..The combination of autophagy modulation and molecular targeted therapy is a promising therapeutic strategy in treatment of HCC...
  30. ncbi Sorafenib for the treatment of advanced renal cell carcinoma
    Robert C Kane
    Division of Drug Oncology Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0004, USA
    Clin Cancer Res 12:7271-8. 2006
    ..S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a new small-molecule, oral, multi-kinase inhibitor for the treatment of patients with advanced renal cell carcinoma (RCC)...
  31. ncbi The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib
    Hayato Hikita
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Hepatology 52:1310-21. 2010
    ..Sorafenib, not alone but in combination with ABT-737, efficiently induced apoptosis in hepatoma cells. This combination also led to stronger suppression of xenograft tumors than sorafenib alone...
  32. ncbi Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial
    Ghassan K Abou-Alfa
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    JAMA 304:2154-60. 2010
    ..The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial...
  33. pmc AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
    Patrick P Zarrinkar
    Ambit Biosciences, San Diego, CA 92121, USA
    Blood 114:2984-92. 2009
    ....
  34. ncbi A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
    K N Chi
    Department of Medical Oncology, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia
    Ann Oncol 19:746-51. 2008
    ..The purpose of this trial was to evaluate the antitumor activity of sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis, in patients with castration-resistant prostate cancer...
  35. pmc SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
    Anthony B El-Khoueiry
    University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Suite 3459, Los Angeles, CA 90033, USA
    Invest New Drugs 30:1646-51. 2012
    ..Based on the role of the Ras-Raf-Mek-Erk pathway and the VEGF axis in biliary carcinomas, we conducted a phase II study of sorafenib in patients with advanced biliary cancers...
  36. ncbi Sorafenib inhibits transforming growth factor β1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes
    Yue Lei Chen
    Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
    Hepatology 53:1708-18. 2011
    ....
  37. pmc A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
    D S Boss
    Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Br J Cancer 106:1598-604. 2012
    ....
  38. pmc Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure
    Nizar M Tannir
    University of Texas, MD Anderson Cancer Center, Houston, 77030, USA
    Eur J Cancer 47:2706-14. 2011
    ..This study assessed the efficacy and safety of linifanib in patients with advanced renal cell carcinoma (RCC) who were previously treated with sunitinib...
  39. ncbi Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors
    Kazuhiko Yamada
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Clin Cancer Res 17:2528-37. 2011
    ..This Phase I study investigated maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in patients with advanced solid tumors...
  40. ncbi Molecular mechanisms of sorafenib action in liver cancer cells
    Melchiorre Cervello
    Institute of Biomedicine and Molecular Immunology Alberto Monroy, National Research Council CNR, Palermo, Italy
    Cell Cycle 11:2843-55. 2012
    ..Further functional analyses may determine whether these genes can serve as potential molecular targets for more effective anti-HCC strategies...
  41. ncbi Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
    Julien Edeline
    Department of Medical Oncology, Eugene Marquis Center, Rennes, France
    Cancer 118:147-56. 2012
    ..In the current study, mRECIST were evaluated and were compared with RECIST in patients who received Sor for advanced HCC...
  42. pmc The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma
    Xu Dong Qu
    Department of Radiology, Zhong Shan Hospital, Fudan University, Fenglin Road, Shanghai 200032, People s Republic of China
    BMC Cancer 12:263. 2012
    ..The present study sought to understand the efficacy of the combination of TACE and sorafenib in the treatment of advanced HCC...
  43. ncbi Sorafenib: a clinical and pharmacologic review
    Renuka Iyer
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Expert Opin Pharmacother 11:1943-55. 2010
    ..Sorafenib is approved for the treatment of advanced inoperable hepatocellular cancer and advanced renal cell cancer...
  44. ncbi Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation
    W Zhao
    State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China
    Leukemia 22:1226-33. 2008
    ..These findings suggest that sorafenib may cause the loss of T-cell immune response by inducing apoptosis and targeting LCK. This could potentially lead to immunosuppression in patients with cancer...
  45. ncbi Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
    B Blanchet
    Laboratoire de Pharmacologie Toxicologie, Service de Pharmacie, France
    J Pharm Biomed Anal 49:1109-14. 2009
    ..Finally, large interindividual variability and higher exposure in patients experiencing severe toxicity support the need for therapeutic drug monitoring to ensure an optimal exposure to sorafenib...
  46. ncbi Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy
    Christina K Augustine
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Mol Cancer Ther 9:2090-101. 2010
    ..These results show that sorafenib in combination with chemotherapy provides a novel approach to enhance chemotherapeutic efficacy in the regional treatment of in-transit melanoma...
  47. ncbi Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area
    Ju Hyun Shim
    Center for Liver Cancer, National Cancer Center, 809 Madu 1 dong, Ilsan gu, Goyang, Goyang, Gyeonggi, 411 769, Republic of Korea
    J Cancer Res Clin Oncol 135:617-25. 2009
    ..This study was conducted to assess the efficacy and safety of sorafenib monotherapy in clinical practice settings for Korean patients with hepatocellular carcinoma (HCC) related primarily to HBV infection...
  48. ncbi Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats
    Marc Mejias
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, CIBERehd, Barcelona, Spain
    Hepatology 49:1245-56. 2009
    ..Notably, beneficial effects of sorafenib against tissue damage and inflammation were also observed in splanchnic organs...
  49. ncbi Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation
    Mohamed Rahmani
    Departments of Medicine, Biochemistry, and Pharmacology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia 23298
    J Biol Chem 280:35217-27. 2005
    ..Together, these findings demonstrate that BAY 43-9006 mediates cell death in human leukemia cells, at least in part, through down-regulation of Mcl-1 via inhibition of translation...
  50. pmc Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells
    Shengbing Huang
    Divisions of Oncology and Gastroenterology Hepatology, Mayo Cancer Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Cancer Ther 9:742-50. 2010
    ..These data indicate that targeting STAT3 may enhance treatment efficacy against pancreatic cancer...
  51. ncbi Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
    Walter M Stadler
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois
    Cancer 116:1272-80. 2010
    ..The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval...
  52. ncbi Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT
    Laure S Fournier
    Department of Radiology, Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, 20 rue Leblanc, Paris 75015, France FR
    Radiology 256:511-8. 2010
    ....
  53. pmc FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
    Keith W Pratz
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Blood 115:1425-32. 2010
    ..These results have important implications for the potential therapeutic use of FLT3 inhibitors in that patients with newly diagnosed FLT3-mutant AML might be less likely to respond clinically to highly selective FLT3 inhibition...
  54. pmc Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site
    Gareth T Young
    Department of Neuroscience, Physiology and Pharmacology, University College London, Gower Street, London WC1E 6BT, United Kingdom
    Proc Natl Acad Sci U S A 105:14686-91. 2008
    ..Our findings suggest that this is a conserved modulatory allosteric site within neurotransmitter-gated ion channels...
  55. ncbi Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
    Keith T Flaherty
    Massachusetts General Hospital, 55 Fruit St, Yawkey 9E, Boston, MA 02114, USA
    J Clin Oncol 31:373-9. 2013
    ..The primary objective of this study was to determine whether carboplatin, paclitaxel, and sorafenib (CPS) improve overall survival (OS) compared with carboplatin and paclitaxel (CP) in chemotherapy-naive patients with metastatic melanoma...
  56. ncbi Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study
    Clemens C Cyran
    Department of Clinical Radiology, Center for Experimental Radiology, University Hospitals Munich, Campus Grosshadern, Ludwig Maximilians University Munich, Marchioninistrasse 15, 81377 Munich, Germany
    AJR Am J Roentgenol 198:384-91. 2012
    ....
  57. ncbi New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis
    Yan Wang
    Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Shijiazhuang, Hebei, China
    J Hepatol 53:132-44. 2010
    ....
  58. ncbi Effect of sorafenib on murine liver regeneration
    Caroline Hora
    Department of Clinical Research, University of Bern, Switzerland
    Hepatology 53:577-86. 2011
    ..An increase of VEGF-A levels was observed in mice receiving sorafenib. Wound-healing complications were observed in animals receiving sorafenib after surgery and confirmed on histological sections...
  59. pmc Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
    Pippa Newell
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    J Hepatol 51:725-33. 2009
    ..We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models...
  60. ncbi Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats
    Kohtaro Abe
    Department of Pharmacology, University of South Alabama, Mobile, Alabama, USA
    Am J Respir Cell Mol Biol 45:804-8. 2011
    ..Vascular smooth muscle relaxation mediated via activation of myosin light chain phosphatase (Ca(2+) desensitization) appears to play a role in the imatinib-induced pulmonary vasodilation...
  61. ncbi Erg K+ channels modulate contractile activity in the bovine epididymal duct
    Marco Mewe
    Institute of Vegetative Physiology and Pathophysiology, University Medical Center, Hamburg Eppendorf, Hamburg, Germany
    Am J Physiol Regul Integr Comp Physiol 294:R895-904. 2008
    ..In summary, these data provide strong evidence for a physiological role of erg1 channels in regulating epididymal motility patterns...
  62. pmc The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma
    R Cabrera
    Division of Gastroenterology, Hepatology and Nutrition, Section of Hepatobiliary Diseases, Department of Medicine, University of Florida, Gainesville, FL 32610 0214, USA
    Aliment Pharmacol Ther 34:205-13. 2011
    ..Standard of practice involves using transarterial therapy for multifocal hepatocellular carcinoma (HCC) alone and sorafenib only for more advanced HCC, but the sorafenib and transarterial therapy combination may provide greater efficacy...
  63. pmc Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth
    C Dudgeon
    Department of Pharmacology and Chemical Biology, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Oncogene 31:4848-58. 2012
    ..They provide a rationale for manipulating the apoptotic machinery to improve sensitivity and overcome resistance to the therapies that target oncogenic kinase signaling...
  64. ncbi Sorafenib for the treatment of unresectable hepatocellular carcinoma
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993 0004, USA
    Oncologist 14:95-100. 2009
    ..Montville, NJ, and Onyx Pharmaceuticals Corp., Emeryville, CA), an oral kinase inhibitor, for the treatment of patients with unresectable hepatocellular carcinoma (HCC)...
  65. ncbi Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by α7 and β2* nicotinic stimulation
    Laura del Barrio
    Instituto Teofilo Hernando, Facultad de Medicina, Universidad Auto noma de Madrid, 28029 Madrid, Spain
    Toxicol Sci 123:193-205. 2011
    ..Therefore, targeting nAChR could offer a strategy for reducing neurodegeneration secondary to hyperphosphorylation of protein τ...
  66. ncbi Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
    Hedy Lee Kindler
    Department of Medicine, Section of Hematology Oncology, University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Invest New Drugs 30:382-6. 2012
    ..Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-β, has activity against pancreatic cancer in preclinical models. In a phase I trial of gemcitabine plus sorafenib, 57% of pancreatic cancer patients achieved stable disease...
  67. ncbi Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas
    Clemens C Cyran
    Department of Clinical Radiology, Center for Experimental Radiology, University Hospitals Munich Campus Grosshadern, Ludwig Maximilians University Munich, Munich, Germany
    Invest Radiol 47:49-57. 2012
    ....
  68. ncbi Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
    Laurence Albiges
    Medical Oncology Department, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
    J Clin Oncol 30:482-7. 2012
    ..It remains a matter of debate whether therapy should be continued after CR...
  69. ncbi Phase II study of sorafenib in patients with relapsed or refractory lymphoma
    Anna Guidetti
    Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
    Br J Haematol 158:108-19. 2012
    ..Sorafenib was well tolerated and had a clinical activity that warrants development of combination regimens...
  70. ncbi A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
    William J Gradishar
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Eur J Cancer 49:312-22. 2013
    ....
  71. ncbi Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity
    Kuen Feng Chen
    Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
    Eur J Med Chem 55:220-7. 2012
    ..In light of the pivotal role of phospho-STAT3 in promoting tumorigenesis and drug resistance, this novel SHP-1-activating agent may have therapeutic relevance in cancer therapy...
  72. ncbi Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice
    Giovan Giuseppe Di Costanzo
    Liver Unit, Cardarelli Hospital, Naples, Italy
    Dig Liver Dis 44:788-92. 2012
    ..Sorafenib is currently the only approved systemic treatment for hepatocellular carcinoma...
  73. ncbi Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
    Tim Eisen
    Cambridge University Health Partners, Cambridge, UK
    Lancet Oncol 13:1055-62. 2012
    ..This phase 2, open-label, non-randomised study assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal-cell carcinoma...
  74. ncbi Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review
    Xin Zhang
    Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Shanghai Key Laboratory for Organ Transplantation, Shanghai 200032, China
    Hepatobiliary Pancreat Dis Int 11:458-66. 2012
    ..This study aimed to assess the efficacy and safety of sorafenib in advanced HCC patients and explore its true value for specific subgroups...
  75. ncbi Forchlorfenuron, a phenylurea cytokinin, disturbs septin organization in Saccharomyces cerevisiae
    Masayuki Iwase
    Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Hongo, Tokyo 113 0033, Japan
    Genes Genet Syst 79:199-206. 2004
    ..Taken together, these findings indicate that FCF maybe a promising drug for investigating the structure and function of septin...
  76. ncbi Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
    R Swords
    Sylvester Comprehensive Cancer Center, University of Miami Leonard M Miller School of Medicine, Miami, FL, USA
    Leukemia 26:2176-85. 2012
    ..Novel combination regimens are also discussed...
  77. pmc BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing
    Aditi Pandya Martin
    Department of Biochemistry and Molecular Biology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298 0035, USA
    Mol Pharmacol 76:327-41. 2009
    ....
  78. ncbi Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy
    Sammy Saab
    Departments of Medicine, The University of California at Los Angeles, Los Angeles, CA, USA
    Exp Clin Transplant 8:307-13. 2010
    ..Liver transplant can be a definitive treatment for hepatocellular carcinoma. However, recurrence limits long-term survival. Sorafenib is the first agent to improve survival for patients with advanced hepatocellular carcinoma...
  79. ncbi Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma
    Mohit Kasibhatla
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Clin Genitourin Cancer 5:291-4. 2007
    ..This combination is promising and requires further study...
  80. ncbi Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
    Da Liang Ou
    National Center of Excellence for Clinical Trial and Research, Department of Oncology, National Taiwan University Hospital, Graduate Institute of Toxicology, Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan
    Cancer Res 70:9309-18. 2010
    ..Together, our findings suggest that GADD45β induction contributes to sorafenib-induced apoptosis in HCC cells, prompting further studies to validate its potential value in predicting sorafenib efficacy...
  81. pmc Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
    D Strumberg
    Department of Hematology and Medical Oncology, University of Bochum, Marienhospital Herne, Hölkeskampring 40, D 44625 Herne, Germany
    Br J Cancer 106:1722-7. 2012
    ..In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour patients. The study was expanded to focus on patients with metastatic colorectal cancer (CRC)...
  82. pmc The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells
    Rui Huang
    Department of Nuclear Medicine, National Key Discipline of Medical Imaging and Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China
    Asian J Androl 12:527-34. 2010
    ..In conclusion, sorafenib induces apoptosis through a caspase-dependent mechanism with down-regulated anti-apoptotic proteins in androgen-independent prostate cancer cells in vitro...
  83. ncbi Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma
    Dmitry A Nosov
    Blokhin Oncology Research Center, Russia
    J Clin Oncol 30:1678-85. 2012
    ..The antitumor activity and safety of tivozanib, which is a potent and selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, was assessed in patients with advanced/metastatic renal cell carcinoma (RCC)...
  84. ncbi Sorafenib and radiation: a promising combination in colorectal cancer
    Andrew W Suen
    Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA
    Int J Radiat Oncol Biol Phys 78:213-20. 2010
    ..To examine the combination of radiation and the multikinase inhibitor sorafenib in human colorectal cancer cell lines and xenografts...
  85. ncbi Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases
    Camillo Porta
    IRCCS San Matteo University Hospital Foundation, Pavia, Italy
    BJU Int 108:E250-7. 2011
    ..To conduct a retrospective, multicentre, cohort analysis to assess the sequential use of the tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib...
  86. ncbi Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Lancet 381:303-12. 2013
    ..An international phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients...
  87. ncbi Toxicity of sorafenib: clinical and molecular aspects
    Benoit Blanchet
    Laboratoire de Pharmacologie Toxicologie, Service de Pharmacie, GH Cochin Saint Vincent de Paul, 75014 Paris, France
    Expert Opin Drug Saf 9:275-87. 2010
    ..Despite its inherent selectivity, sorafenib can cause unusual adverse events whose the management represents a challenge for oncologists...
  88. pmc Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
    Bruno Vincenzi
    Department of Surgical and Oncological Sciences, Section of Medical Oncology Università di Palermo, Palermo, Italy, Via del Vespro 127, 90127 Palermo, Italy
    Oncologist 15:85-92. 2010
    ..This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients...
  89. ncbi A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors
    Klaus Mross
    Tumour Biology Center, University Hospital, Freiburg, Germany
    Clin Cancer Res 18:2658-67. 2012
    ..This first-in-man, phase I dose-escalation study assessed the safety, pharmacokinetic, pharmacodynamic, and efficacy profiles of regorafenib in patients with advanced solid tumors...
  90. ncbi XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells
    Yan Liu
    Center for Childhood Cancer, Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, 43205, USA
    Apoptosis 16:502-10. 2011
    ..These results suggested that XZH-5 may serve as a lead compound for further development of STAT3 specific small molecule inhibitors for HCC therapy...
  91. ncbi Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3
    Kuen Feng Chen
    Department of Medical Research, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    Clin Cancer Res 16:5189-99. 2010
    ..However, many hepatocellular carcinoma (HCC) cells show resistance to TRAIL-induced apoptosis. Here, we report that sorafenib improves the antitumor effect of TRAIL-related agents in resistant HCC...
  92. pmc Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology, Mayo Clinic and Mayo Foundation, Jacksonville, FL 32224, USA
    J Clin Oncol 27:11-5. 2009
    ..We conducted a cooperative group phase II study to assess antitumor activity and toxicity of sorafenib in patients with metastatic breast cancer (MBC) who had received prior treatment for their disease...
  93. ncbi Sorafenib: a review of its use in advanced hepatocellular carcinoma
    Gillian M Keating
    Wolters Kluwer Health mid R Adis, Auckland, New Zealand
    Drugs 69:223-40. 2009
    ....
  94. pmc Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
    D Handolias
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Br J Cancer 102:1219-23. 2010
    ..Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation...
  95. ncbi Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells
    Erika Martinelli
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Napoli, Italy
    Clin Cancer Res 16:4990-5001. 2010
    ..Cancer cell survival, invasion, and metastasis depend on cancer cell proliferation and on tumor-induced angiogenesis. We evaluated the efficacy of the combination of sorafenib and erlotinib or cetuximab...
  96. ncbi Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway
    Chang Liang Peng
    Musculoskeletal Tumor Center, Peking University Peoples Hospital, Beijing, China
    Cancer Biol Ther 8:1729-36. 2009
    ..In conclusion, our findings demonstrate that sorafenib is effective for growth inhibition of synovial sarcoma cell lines in vitro and suggest that sorafenib may be a new therapeutic option for patients with synovial sarcoma...
  97. pmc Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420
    Stephen K Williamson
    University of Kansas Cancer Center, Hematology Oncology Division, Westwood, KS 66205, USA
    J Clin Oncol 28:3330-5. 2010
    ..The primary end point was response probability (ie, confirmed complete and partial response [PR])...
  98. pmc Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2
    Boris R A Blechacz
    Division of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 50:1861-70. 2009
    ..In this in vivo model, sorafenib also decreased tumor Tyr(705) STAT3 phosphorylation and increased tumor cell apoptosis...
  99. ncbi Renal cell carcinoma
    Brian I Rini
    Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
    Curr Opin Oncol 20:300-6. 2008
    ..This study is intended to update prognostic and therapeutic decision-making data and provide perspective on advances in understanding the molecular biology of this disease...
  100. ncbi Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation
    Richard Kim
    Department of Gastrointestinal Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA richard kim moffitt org
    Oncology 79:62-6. 2010
    ..However, 10-15% of patients will have reoccurrence after OLT. Currently, sorafenib is available for advanced HCC. The safety and efficacy of sorafenib in this population has not been reported...
  101. ncbi Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation
    Bjoern Chapuy
    Department of Haematology and Oncology, Georg August University Goettingen, Germany
    Br J Haematol 152:401-12. 2011
    ..In conclusion, sorafenib has significant in vitro efficacy against aggressive B- and T-cell lymphoma cells, associated with inhibition of MAPK14 and panAKT...

Research Grants39

  1. Therapeutic Modulation of COX-2-induced Immunosuppression in Metastatic RCC
    Brian Rini; Fiscal Year: 2008
    ..This project will have broad implications for the immunoregulation of cancer and how expression and modulation of COX-2 expression influences the immune response to cancer. [unreadable] [unreadable] [unreadable]..
  2. Combination Strategies for Angiogenesis Inhibition
    Keith Flaherty; Fiscal Year: 2008
    ..He is a recognized leader in the field of investigational therapies, has a record of mentoring successful clinical researchers, and is committed to Dr. Flaherty's training. ..
  3. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert J Motzer; Fiscal Year: 2011
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  4. CLINICAL TRIALS AND MENTORING IN ONCOLOGY RESEARCH
    Robert Motzer; Fiscal Year: 2003
    ..One recently joined staff at MSKCC in the Genito-urinary Section. Mentoring of clinical trials is extended beyond fellowship to junior faculty members. ..
  5. ITEM BANKING AND CAT FOR QUALITY OF LIFE OUTCOMES
    David Cella; Fiscal Year: 2008
    ..We will also monitor treatment/management changes, and evaluate acceptability of computer assessments and the perceived benefits of the recommendations. ..
  6. Brca1 Deletion in Murine Cells and Mammary Tissue
    MARCIA BROSE; Fiscal Year: 2007
    ..abstract_text> ..
  7. FRA16D CHROMOSOMAL FRAGILE SITE IN LIVER CARCINOGENESIS
    Lewis Roberts; Fiscal Year: 2003
    ..This will enable me to obtain the training and preliminary data I need to launch an independent, productive research career. ..
  8. Dose and Treatment Selection in Clinical Trials
    Ying Kuen Cheung; Fiscal Year: 2010
    ....
  9. CANCER GENETICS NETWORK
    Claudine Isaacs; Fiscal Year: 2006
    ....
  10. BIOLOGIC MODIFIER THERAPIES IN AIDS MALIGNANCIES
    Manisha Shah; Fiscal Year: 2004
    ..Collectively, this application provides enhanced strength in intellectual contributions and patient accrual for the AMC, compared to our previous application. ..
  11. Cytosolic Phospholipase A2 in Cardiac Hypertrophy
    Thomas Force; Fiscal Year: 2005
    ..abstract_text> ..
  12. Discovery of Novel Cytotoxic Agents for Advanced Melanoma
    Wei Li; Fiscal Year: 2008
    ..This is a high risk, innovative proposal to discover a non-surgical means for a more selective and curative pharmacologic therapy for advanced melanoma. [unreadable] [unreadable] [unreadable]..
  13. Aurora Kinases as Therapeutic Targets in Pancreatic Cancer
    Daniel D Von Hoff; Fiscal Year: 2010
    ..The results generated from this project therefore have the potential to directly benefit pancreatic cancer patients with improved treatment and the general public with reduced healthcare cost. ..
  14. CANCER AND LEUKEMIA GROUP B--PET COMMITTEE
    Mark Ratain; Fiscal Year: 2002
    ..Since many of the studies include analysis of pharmacological specimens, the Committee utilizes three core laboratories--at the University of Chicago, the University of Maryland and the University of Tennessee. ..
  15. Skin Manifestations of Tuberous Sclerosis
    Jack Arbiser; Fiscal Year: 2009
    ..Specific Aim 3. To determine whether dysregulation of p16ink4a and PTCH (patched) acts as a modifier of theTS phenotype in transgenic mice expressing dominant negative tuberin. ..
  16. Research Echocardiography System
    Thomas Force; Fiscal Year: 2004
    ....
  17. MENTORED ORIENTED RESEARCH CAREER DEVELOPMENT AWARD
    Jared Gollob; Fiscal Year: 2004
    ....
  18. MOLECULAR PATHOGENESIS OF HEPATOCELLULAR CARCINOMA
    Lewis Roberts; Fiscal Year: 2008
    ..Successful completion of these studies will provide insight into the molecular pathogenesis of HCC, and may lead to the development of novel chemotherapeutic strategies against HCC. ..
  19. Clinical Trials Methods Workshop - Europe
    Daniel Von Hoff; Fiscal Year: 2008
    ..And, finally, a proven evaluation system is in place to demonstrate that the Workshop will meet its objectives. ..
  20. The Renin-Angiotensin System in Hepatitis and Hepatoma
    Mary Maluccio; Fiscal Year: 2008
    ..The preclinical model involves a human hepatitis derived hepatocellular carcinoma xenograft into an immunodeficient mouse. [unreadable] [unreadable] [unreadable]..
  21. K Vitamins- A New Class of Liver Cell Growth Inhibitors
    Brian Carr; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  22. Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    David Reardon; Fiscal Year: 2004
    ..To further define the toxicity of this approach and Specific Aim 3.To determine the impact of this therapy on quality of life. ..
  23. NOVEL A RING AND E RING MODIFIED CAMPTOTHECIN ANALOGS
    Daniel Von Hoff; Fiscal Year: 2001
    ..abstract_text> ..
  24. Targeting RAF and VEGF Signaling in Thyroid Cancer
    Manisha Shah; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  25. Mechanism of SHeA2 Action in Ovarian Cancer
    Doris Benbrook; Fiscal Year: 2009
    ..The elucidation of the proteins involved in the SHetA2 pathwayswill provide potential biomarkers for ovarian cancer diagnosis, prevention and treatment strategies. ..
  26. FASEB Summer Conference on Microbial Polysaccharides
    Arthur Tzianabos; Fiscal Year: 2004
    ..This meeting will provide a unique environment for scientific exchange between a diverse group of investigators in the area of microbial polysaccharides. ..
  27. ACUTE TOLERANCE IN ANESTHETIC ACTIONS AND INTERACTIONS
    Igor Kissin; Fiscal Year: 2001
    ....
  28. Cytokine induction of Claudin-1 in epicardial border zone of ischemic heart
    Heather S Duffy; Fiscal Year: 2010
    ..We also propose to use sophisticated computer modeling to assess the impact on propagation that the addition of these extracellular barriers would provide. ..
  29. Mechanisms linking the adipogenic phenotype of aging muscle to insulin resistance
    Deborah M Muoio; Fiscal Year: 2010
    ....
  30. Steroids and Stem Cell in Carcinogenesis
    Doris Benbrook; Fiscal Year: 2004
    ..This research will enhance our understanding of the process of carcinogenesis and chemoprevention, which could ultimately translate into strategies and pharmaceuticals for prevention of cancer. ..
  31. Neural blockade with vanilloids
    Igor Kissin; Fiscal Year: 2007
    ..To study the specific aims of the project the effects of RTX will be examined in rats by behavioral methods; and whole cell voltage-clamp technique will be used to identify a mechanism for impulse failure induced by RTX. ..
  32. Surgical Adhesions: Role of T cells in Pathogenesis
    Arthur Tzianabos; Fiscal Year: 2005
    ..abstract_text> ..
  33. Chemokine Blockade to Preserve Lung Development
    Richard Auten; Fiscal Year: 2005
    ..Aim 3 will determine whether blockade of leukocyte function can safely preserve normal alveolar development during recovery from severe oxidant stress. ..
  34. Development of Novel VEGF Analogs
    Mariusz Szkudlinski; Fiscal Year: 2005
    ..In the subsequent Phase II studies we will assess the therapeutic potential of VEGF analogs using animal models of angiogenesis and tumorigenesis. ..
  35. Host Response in S. aureus Infections: Role of T cells
    Arthur Tzianabos; Fiscal Year: 2006
    ..aureus infections. This information may reveal new strategies for the prevention or treatment of S. aureus infections through immunomodulation of the host response to this organism. ..
  36. Ketone Dysregulation and Muscle Insulin Resistance
    DEBORAH MUOIO; Fiscal Year: 2006
    ..abstract_text> ..
  37. TEACHING BIOLOGY THROUGH IMMUNOLOGY FELLOWSHIPS
    Arthur Tzianabos; Fiscal Year: 2007
    ..Thus, we will also survey each teacher and school district previously in the program in order to determine the effect of the program on science education and student career choices. [unreadable] [unreadable]..
  38. Studying nicotinic AChRs in histaminergic neurons
    VICTOR UTESHEV GAARD; Fiscal Year: 2007
    ..Some of these effects of nicotine and therapeutic nicotinic agents may arise from their ability to modulate histaminergic function. [unreadable] [unreadable]..